Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins
- 10 September 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (17), 9070-9092
- https://doi.org/10.1021/acs.jmedchem.0c00605
Abstract
Pan-bromodomain and extra terminal domain (BET) inhibitors interact equipotently with the eight bromodomains of the BET family of proteins and have shown profound efficacy in a number of in vitro phenotypic assays and in vivo pre-clinical models in inflammation or oncology. A number of these inhibitors have progressed to the clinic where pharmacology-driven adverse events have been reported. To better understand the contribution of each domain to their efficacy and improve their safety profile, selective inhibitors are required. This article discloses the profile of GSK046, also known as iBET-BD2, a highly selective inhibitor of the second bromodomains of the BET proteins that has undergone extensive pre-clinical in vitro and in vivo characterization.This publication has 53 references indexed in Scilit:
- The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancerOncogene, 2017
- AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesMolecular Cancer Therapeutics, 2016
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted DrugsClinical Cancer Research, 2015
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762Blood, 2014
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic TherapyCancer Research, 2013
- PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET BromodomainsCancer Research, 2013
- Inhibition of BET Bromodomain Targets Genetically Diverse GlioblastomaClinical Cancer Research, 2013
- Place your BETs: the therapeutic potential of bromodomainsTrends in Pharmacological Sciences, 2012
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Selective inhibition of BET bromodomainsNature, 2010